Search for: "Does 1 - 23" Results 401 - 420 of 15,297
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Feb 2024, 2:13 pm by Katie Calogero
If the agency does not adequately document its rationale, especially in light of contradicting facts, the GAO will find the record does not demonstrate the agency’s evaluation was reasonable. [read post]
29 Feb 2024, 10:06 am by Dennis Crouch
Ex parte Goytia, 23-4166 (P.T.A.B. [read post]
29 Feb 2024, 12:00 am by Hayleigh Bosher
 The only relief for Sony at the hands of Justice Green came with the ruling that he would strike out the allegations made by the claimants that Sony had knowingly committed secondary infringement of copyright under sections 23 and 24 of the CDPA. [read post]
28 Feb 2024, 10:30 pm by Marjut Salokannel
(recital 37a) … Where a Member State does not introduce a specific right to object in accordance with article 35F of this regulation, solely Article 21 of Regulation (EU) 2016/679 will apply. [read post]
28 Feb 2024, 2:00 pm
The trial court’s gatekeeping role does not involve choosing between competing expert opinions. [read post]
27 Feb 2024, 2:21 pm by centerforartlaw
Disputes can arise when an agreement does not clearly outline terms related to payment and costs. [read post]
27 Feb 2024, 10:16 am by Courtney Finerty-Stelzner
On June 23, 2022, the United States Supreme Court, in New York State Rifle & Pistol Association, Inc. et al. v. [read post]
26 Feb 2024, 7:00 am
District Court for the Northern District of Illinois (Civil Action No.1:23-cv-14110), seeking monetary damages and injunctive relief.In a press release released in late January, the EEOC announced a settlement of the dispute, wherein Blackwell agreed to pay $70,000 to the impacted individual and further agreed to modify its training and employment related practices to comply with federal law.In a written statement, Gregory Gochanour, regional attorney for the EEOC’s Chicago… [read post]
26 Feb 2024, 2:26 am by Kurt R. Karst
Boehringer Ingelheim submitted a Citizen Petition in December 2020 encouraging FDA to interpret the term “strength” under the BPCIA differently than the Agency does under the Hatch-Waxman Act. [read post]